OBJECTIVES: Published data have reported that components of the peripheral blood are significant prognostic factors in hematologic and solid malignancies. Thus, we sought to investigate if the preoperative absolute lymphocyte count (ALC) and absolute monocyte count (AMC) affects disease progression and survival after complete surgical resection of advanced malignant melanoma. METHODS: We retrospectively reviewed records of 227 patients with resected advanced malignant melanoma (153 stage III and 74 stage IV) that were treated at the Mayo Clinic from 2000 to 2010. Survival analysis was performed using the Kaplan-Meier method, log-rank tests, and the Cox proportional hazards model for the univariate and multivariate analysis. RESULTS: Surgically resected stage III melanoma patients with a preoperative AMC<0.6×10/L experienced a longer overall survival (OS) versus AMC≥0.6×10/L (median: 63.9 vs. 34.8 mo, respectively, P<0.008). Multivariate analysis showed AMC to be an independent predictor for OS in stage III patients. Stage IV resected melanoma patients with an ALC≥1.9×10/L experienced a superior median relapse-free survival (RFS) compared with patients with an ALC<1.9×10/L (median: 11.4 vs. 5.4 mo, respectively, P<0.006). Multivariate analysis showed ALC to be an independent predictor for RFS in stage IV patients. CONCLUSIONS: These data showed that in surgically resected stage III melanoma, preoperative AMC is an independent prognostic factor for OS. In contrast, a higher preoperative ALC is an independent prognostic for longer RFS in surgically resected stage IV melanoma.
OBJECTIVES: Published data have reported that components of the peripheral blood are significant prognostic factors in hematologic and solid malignancies. Thus, we sought to investigate if the preoperative absolute lymphocyte count (ALC) and absolute monocyte count (AMC) affects disease progression and survival after complete surgical resection of advanced malignant melanoma. METHODS: We retrospectively reviewed records of 227 patients with resected advanced malignant melanoma (153 stage III and 74 stage IV) that were treated at the Mayo Clinic from 2000 to 2010. Survival analysis was performed using the Kaplan-Meier method, log-rank tests, and the Cox proportional hazards model for the univariate and multivariate analysis. RESULTS: Surgically resected stage III melanoma patients with a preoperative AMC<0.6×10/L experienced a longer overall survival (OS) versus AMC≥0.6×10/L (median: 63.9 vs. 34.8 mo, respectively, P<0.008). Multivariate analysis showed AMC to be an independent predictor for OS in stage III patients. Stage IV resected melanomapatients with an ALC≥1.9×10/L experienced a superior median relapse-free survival (RFS) compared with patients with an ALC<1.9×10/L (median: 11.4 vs. 5.4 mo, respectively, P<0.006). Multivariate analysis showed ALC to be an independent predictor for RFS in stage IV patients. CONCLUSIONS: These data showed that in surgically resected stage III melanoma, preoperative AMC is an independent prognostic factor for OS. In contrast, a higher preoperative ALC is an independent prognostic for longer RFS in surgically resected stage IV melanoma.
Authors: Peter D Boasberg; Dave S B Hoon; Lawrence D Piro; Maureen A Martin; Akhide Fujimoto; Timothy S Kristedja; Sandeep Bhachu; Xing Ye; Regina R Deck; Steven J O'Day Journal: J Invest Dermatol Date: 2006-08-31 Impact factor: 8.551
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Mustaqeem Siddiqui; Kay Ristow; Svetomir N Markovic; Thomas E Witzig; Thomas M Habermann; Joseph P Colgan; David J Inwards; William L White; Stephen M Ansell; Ivana N Micallef; Patrick B Johnston; Timothy G Call; Luis F Porrata Journal: Br J Haematol Date: 2006-08-01 Impact factor: 6.998
Authors: C Joao; L F Porrata; D J Inwards; S M Ansell; I N Micallef; P B Johnston; D A Gastineau; S N Markovic Journal: Bone Marrow Transplant Date: 2006-05 Impact factor: 5.483
Authors: Luis F Porrata; David J Inwards; Stephen M Ansell; Ivana N Micallef; Patrick B Johnston; Dennis A Gastineau; Mark R Litzow; Jeffrey L Winters; Svetomir N Markovic Journal: Biol Blood Marrow Transplant Date: 2008-07 Impact factor: 5.742
Authors: Dusan Bogunovic; David W O'Neill; Ilana Belitskaya-Levy; Vladimir Vacic; Yi-Lo Yu; Sylvia Adams; Farbod Darvishian; Russell Berman; Richard Shapiro; Anna C Pavlick; Stefano Lonardi; Jiri Zavadil; Iman Osman; Nina Bhardwaj Journal: Proc Natl Acad Sci U S A Date: 2009-11-13 Impact factor: 11.205
Authors: Alexander Martens; Kilian Wistuba-Hamprecht; Marnix Geukes Foppen; Jianda Yuan; Michael A Postow; Phillip Wong; Emanuela Romano; Amir Khammari; Brigitte Dreno; Mariaelena Capone; Paolo A Ascierto; Anna Maria Di Giacomo; Michele Maio; Bastian Schilling; Antje Sucker; Dirk Schadendorf; Jessica C Hassel; Thomas K Eigentler; Peter Martus; Jedd D Wolchok; Christian Blank; Graham Pawelec; Claus Garbe; Benjamin Weide Journal: Clin Cancer Res Date: 2016-01-19 Impact factor: 12.531
Authors: Philipp Nuhn; Ajay M Vaghasia; Jatinder Goyal; Xian C Zhou; Michael A Carducci; Mario A Eisenberger; Emmanuel S Antonarakis Journal: BJU Int Date: 2014-02-14 Impact factor: 5.588
Authors: Edmund K Bartlett; Jessica R Flynn; Katherine S Panageas; Richard A Ferraro; Jessica M Sta Cruz; Michael A Postow; Daniel G Coit; Charlotte E Ariyan Journal: Cancer Date: 2019-10-04 Impact factor: 6.860
Authors: Michael R Cassidy; Rachel E Wolchok; Junting Zheng; Katherine S Panageas; Jedd D Wolchok; Daniel Coit; Michael A Postow; Charlotte Ariyan Journal: EBioMedicine Date: 2017-03-24 Impact factor: 8.143